Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives

References

• Ruparelia N, Chai JT, Fisher EA, et al. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. 2017;14(3):133–144.
   PubMed Web of Science ®Google Scholar
• Hutton HL, Ooi JD, Holdsworth SR, et al. The NLRP3 inflammasome in kidney disease and autoimmunity. Nephrology (Carlton, Vic). 2016;21(9):736–744.
   PubMed Web of Science ®Google Scholar
• Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol. 2019;14(1):50–59.
   PubMed Web of Science ®Google Scholar
• Georgakis MK, Malik R, Li X, et al. Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association study. Circulation. 2021;143(11):1177–1180.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015;14(4):571–582.
   PubMed Web of Science ®Google Scholar
• Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–345.
   PubMed Web of Science ®Google Scholar
• Rose-John S. Interleukin-6 signalling in health and disease. F1000Res. 2020;9:1013.
   Google Scholar
• Wallenius V, Wallenius K, Ahrén B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8(1):75–79.
   PubMed Web of Science ®Google Scholar
• Villar-Fincheira P, Sanhueza-Olivares F, Norambuena-Soto I, et al. Role of interleukin-6 in vascular health and disease. Front Mol Biosci. 2021;8:641734.
   PubMed Web of Science ®Google Scholar
• Kummer KK, Zeidler M, Kalpachidou T, et al. Role of IL-6 in the regulation of neuronal development, survival and function. Cytokine. 2021;144:155582.
   PubMed Web of Science ®Google Scholar
• Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016;1863(6):1218–1227.
   PubMed Web of Science ®Google Scholar
• Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13(7):399–409.
   PubMed Web of Science ®Google Scholar
• Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773–789.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363–369.
   PubMed Web of Science ®Google Scholar
• Arnold N, Lechner K, Waldeyer C, et al. Inflammation and cardiovascular disease: the future. Eur Cardiol. 2021;16:e20.
   PubMed Web of Science ®Google Scholar
• Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015;26(5):475–487.
   PubMed Web of Science ®Google Scholar
• Hundhausen C, Roth A, Whalen E, et al. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci Transl Med. 2016;8(356):356ra119.
   PubMed Web of Science ®Google Scholar
• Schneider A, Long SA, Cerosaletti K, et al. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T regs involves IL-6–Mediated signaling. Sci Transl Med. 2013;5(170):170ra115.
   Web of Science ®Google Scholar
• Schumacher N, Rose-John S. ADAM17 activity and IL-6 trans-signaling in inflammation and cancer. Cancers (Basel). 2019;11(11):1736.
   Web of Science ®Google Scholar
• Schreiber S, Aden K, Bernardes JP, et al. Therapeutic Interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160(7):2354–2366.e2311.
   PubMed Web of Science ®Google Scholar
• Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519–531.
   PubMed Web of Science ®Google Scholar
• Mariette X, Hermine O, Tharaux PL, et al. Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial. JAMA Intern Med. 2021;181(9):1241.
   PubMed Web of Science ®Google Scholar
• von Scholten BJ, Kreiner FF, Gough SCL, et al. Current and future therapies for type 1 diabetes. Diabetologia. 2021;64(64):1037–1048.
   PubMedGoogle Scholar
• Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
   PubMed Web of Science ®Google Scholar
• Khawandanah J. Double or hybrid diabetes: a systematic review on disease prevalence, characteristics and risk factors. Nutr Diabetes. 2019;9(1):33.
   PubMedGoogle Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2019;157:107843. 9(th) edition
   PubMed Web of Science ®Google Scholar
• Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407–1418.
   PubMed Web of Science ®Google Scholar
• Petrie JR, Sattar N. Excess cardiovascular risk in type 1 diabetes mellitus. Circulation. 2019;139(6):744–747.
   PubMed Web of Science ®Google Scholar
• Timper K, Denson JL, Steculorum SM, et al. IL-6 improves energy and glucose homeostasis in obesity via enhanced central IL-6 trans-signaling. Cell Rep. 2017;19(2):267–280.
   PubMed Web of Science ®Google Scholar
• Carey AL, Steinberg GR, Macaulay SL, et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006;55(10):2688–2697.
   PubMed Web of Science ®Google Scholar
• Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88(4):1379–1406.
   PubMed Web of Science ®Google Scholar
• Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17(11):1481–1489.
   PubMed Web of Science ®Google Scholar
• Chen YL, Qiao YC, Pan YH, et al. Correlation between serum interleukin-6 level and type 1 diabetes mellitus: a systematic review and meta-analysis. Cytokine. 2017;94:14–20.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177–185.
   PubMed Web of Science ®Google Scholar
• The diabetes control and complications trial research group, Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The diabetes control and complications trial research group. Ann Intern Med. 1998;128:517–523
   PubMed Web of Science ®Google Scholar
• Zatterale F, Longo M, Naderi J, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol. 2019;10:1607.
   PubMed Web of Science ®Google Scholar
• Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PloS one. 2010;5(12):e14328.
   PubMed Web of Science ®Google Scholar
• Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation–mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012;32(8):1771–1776.
   PubMed Web of Science ®Google Scholar
• Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1–4.
   PubMed Web of Science ®Google Scholar
• van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88(7):3005–3010.
   PubMed Web of Science ®Google Scholar
• Wueest S, Konrad D. The controversial role of IL-6 in adipose tissue on obesity-induced dysregulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2020;319(3):E607–e613.
   PubMed Web of Science ®Google Scholar
• Patsalos O, Dalton B, Himmerich H. Effects of IL-6 signaling pathway inhibition on weight and BMI: a systematic review and meta-analysis. Int J Mol Sci. 2020;21(17):6290.
   Web of Science ®Google Scholar
• Cookson P. The blind leading the blind. Nurs Mirror Midwives J. 1974;139(22):64–65.
   PubMedGoogle Scholar
• Gomes KB. IL-6 and type 1 diabetes mellitus: t cell responses and increase in IL-6 receptor surface expression. Ann Transl Med. 2017;5(1):16.
   PubMed Web of Science ®Google Scholar
• Marwaha AK, Crome SQ, Panagiotopoulos C, et al. Tan R: cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Iimmunol. 2010;185(7):3814–3818. Baltimore, Md: 1950.
   PubMed Web of Science ®Google Scholar
• Bradshaw EM, Raddassi K, Elyaman W, et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Iimmunol. 2009;183(7):4432–4439. Baltimore, Md: 1950.
   PubMed Web of Science ®Google Scholar
• Ferreira RC, Freitag DF, Cutler AJ, et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 2013;9(4):e1003444.
   PubMed Web of Science ®Google Scholar
• Rosa JS, Oliver SR, Flores RL, et al. Altered inflammatory, oxidative, and metabolic responses to exercise in pediatric obesity and type 1 diabetes. Pediatr Diabetes. 2011;12(5):464–472.
   PubMed Web of Science ®Google Scholar
• Bender C, Rajendran S, von Herrath MG. New insights into the role of autoreactive CD8 T cells and cytokines in human type 1 diabetes. Front Endocrinol (Lausanne). 2020;11:606434.
   PubMed Web of Science ®Google Scholar
• Lo HC, Lin SC, Wang YM. The relationship among serum cytokines, chemokine, nitric oxide, and leptin in children with type 1 diabetes mellitus. Clin Biochem. 2004;37(8):666–672.
   PubMed Web of Science ®Google Scholar
• Pestana RM, Domingueti CP, Duarte RC, et al. Cytokines profile and its correlation with endothelial damage and oxidative stress in patients with type 1 diabetes mellitus and nephropathy. Immunol Res. 2016;64(4):951–960.
   PubMed Web of Science ®Google Scholar
• Marasco MR, Conteh AM, Reissaus CA, et al. Interleukin-6 reduces β-cell oxidative stress by linking autophagy with the antioxidant response. Diabetes. 2018;67(8):1576–1588.
   PubMed Web of Science ®Google Scholar
• Jablonowska M, Milnerowicz H, Rabczynski J, et al. Immunohistochemical localization of interleukin-6 in human pancreatitis. Appl Immunohistochem Mol Morphol. 2008;16(1):40–43.
   PubMedGoogle Scholar
• Rajendran S, Anquetil F, Quesada-Masachs E, et al. IL-6 is present in beta and alpha cells in human pancreatic islets: expression is reduced in subjects with type 1 diabetes. Clin Immunol. 2020;211:108320.
   PubMed Web of Science ®Google Scholar
• Greenbaum CJ, Serti E, and Lambert K, et al. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. JCI Insight. 2021;6(21):e150074.
   PubMed Web of Science ®Google Scholar
• Pesce B, Soto L, Sabugo F, et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol. 2013;171(3):237–242.
   PubMed Web of Science ®Google Scholar
• Bowker N, Shah RL, Sharp SJ, et al. Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes. EBioMedicine. 2020;61:103062.
   PubMed Web of Science ®Google Scholar
• Everett BM, Donath MY, Pradhan AD, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018;71(21):2392–2401.
   PubMed Web of Science ®Google Scholar
• Ahluwalia TS, Prins BP, Abdollahi M, et al. Genome-wide association study of circulating interleukin 6 levels identifies novel loci. Hum Mol Genet. 2021;30(5):393–409.
   PubMed Web of Science ®Google Scholar
• Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3:17088.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation (IHME). GBD 2019 cause and risk summary: chronic kidney disease. Seattle [USA]: IHME, University of Washington; 2022. [20 Jan].
   Google Scholar
• Tuttle KR, Alicic RZ, Duru OK, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Network Open. 2019;2(12):e1918169.
   PubMed Web of Science ®Google Scholar
• Andrade-Oliveira V, Foresto-Neto O, Watanabe IKM, et al. Inflammation in renal diseases: new and old players. Front Pharmacol. 2019;10:1192.
   PubMed Web of Science ®Google Scholar
• Koye DN, Magliano DJ, Nelson RG, et al. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25(2):121–132.
   PubMed Web of Science ®Google Scholar
• Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–176.
   PubMed Web of Science ®Google Scholar
• Feigerlová E, Battaglia-Hsu SF. IL-6 signaling in diabetic nephropathy: from pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev. 2017;37:57–65.
   PubMed Web of Science ®Google Scholar
• Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 2007;60(1):18–26.
   PubMed Web of Science ®Google Scholar
• Stephens JW, Brown KE, Min T. Chronic kidney disease in type 2 diabetes: implications for managing glycaemic control, cardiovascular and renal risk. Diabetes Obes Metab. 2020;22(Suppl 1):32–45.
   PubMedGoogle Scholar
• Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344–358.
   PubMed Web of Science ®Google Scholar
• Araújo LS, Torquato BGS, da Silva CA, et al. Renal expression of cytokines and chemokines in diabetic nephropathy. BMC Nephrol. 2020;21(1):308.
   PubMed Web of Science ®Google Scholar
• Taslipinar A, Yaman H, Yilmaz MI, et al. The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy. Scand J Clin Lab Invest. 2011;71(7):606–612.
   PubMed Web of Science ®Google Scholar
• Su H, Lei CT, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol. 2017;8:405.
   PubMed Web of Science ®Google Scholar
• Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010;77(6):550–556.
   PubMed Web of Science ®Google Scholar
• Kiberd BA. Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol. 1993;4(1):58–61.
   PubMed Web of Science ®Google Scholar
• Liang B, Gardner DB, Griswold DE, et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119(3):296–305.
   PubMed Web of Science ®Google Scholar
• Ryffel B, Car BD, Gunn H, et al. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol. 1994;144(5):927–937.
   PubMed Web of Science ®Google Scholar
• Horii Y, Muraguchi A, Iwano M, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Iimmunol. 1989;143:3949–3955.
   PubMed Web of Science ®Google Scholar
• Kronbichler A, Oh J, Meijers B, et al. Focal segmental glomerulosclerosis: genetics, mechanism, and therapies. Biomed Res Int. 2016;2016:9643785.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Glynn RJ, et al. Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol. 2018;71(21):2405–2414.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060–2069.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Devalaraja M, Fishbane S, et al. Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol. 2021;32(1):211–222.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271–1276.
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18(8):555–559.
   PubMed Web of Science ®Google Scholar
• Garimella PS, Katz R, Patel KV, et al. Association of serum erythropoietin with cardiovascular events, kidney function decline, and mortality: the health aging and body composition study. Circ Heart Fail. 2016;9(1):e002124.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rane M. Interleukin-6 signaling and Anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128(11):1728–1746.
   PubMed Web of Science ®Google Scholar
• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
   PubMed Web of Science ®Google Scholar
• Broch K, Anstensrud AK, Woxholt S, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77(15):1845–1855.
   PubMed Web of Science ®Google Scholar
• Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56.
   PubMed Web of Science ®Google Scholar
• Martinez BK, White CM. The emerging role of inflammation in cardiovascular disease. Ann Pharmacother. 2018;52(8):801–809.
   PubMed Web of Science ®Google Scholar
• Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262–271.
   PubMed Web of Science ®Google Scholar
• Montarello NJ, Nguyen MT, Wong DTL, et al. Inflammation in coronary atherosclerosis and its therapeutic implications. Cardiovasc Drugs Ther. 2020. https://doi.org/10.1007/s10557-020-07106-6
   Google Scholar
• Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(39):3499–3507.
   PubMedGoogle Scholar
• Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–328.
   PubMed Web of Science ®Google Scholar
• Aimo A, Pascual-Figal DA, Barison A, et al. Colchicine for the treatment of coronary artery disease. Trends Cardiovasc Med. 2020;31(8):497–504.
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al. Thompson PL: colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847.
   PubMed Web of Science ®Google Scholar
• Boland J, Long C. Update on the inflammatory hypothesis of coronary artery disease. Curr Cardiol Rep. 2021;23(2):6.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Inhibiting interleukin-6 to reduce cardiovascular event rates: a next step for atherothrombosis treatment and prevention. J Am Coll Cardiol. 2021;77(15):1856–1858.
   PubMed Web of Science ®Google Scholar
• Ridker PM. From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 2020;141(10):787–789.
   PubMed Web of Science ®Google Scholar
• Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–156.
   PubMed Web of Science ®Google Scholar
• Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22(3):147–151.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Ott I, Marx N, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol. 1997;17(12):3399–3405.
   PubMed Web of Science ®Google Scholar
• Alsaffar H, Martino N, Garrett JP, et al. Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis. Am J Physiol Cell Physiol. 2018;314(5):C589–c602.
   PubMed Web of Science ®Google Scholar
• Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6(3):315–325.
   PubMed Web of Science ®Google Scholar
• Schuett H, Oestreich R, Waetzig GH, et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32(2):281–290.
   PubMed Web of Science ®Google Scholar
• Zhang K, Huang XZ, Li XN, et al. Interleukin 6 destabilizes atherosclerotic plaques by downregulating prolyl-4-hydroxylase α1 via a mitogen-activated protein kinase and c-Jun pathway. Arch Biochem Biophys. 2012;528(2):127–133.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973–979.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–843.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391–397.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Butterworth AS, and Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205–1213. .
   PubMed Web of Science ®Google Scholar
• Anagnostakos J, Lal BK. Abdominal aortic aneurysms. Prog Cardiovasc Dis. 2021;65:34–43.
   PubMed Web of Science ®Google Scholar
• Rohde LE, Arroyo LH, Rifai N, et al. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler Thromb Vasc Biol. 1999;19(7):1695–1699.
   PubMed Web of Science ®Google Scholar
• Thompson RW, Geraghty PJ, Lee JK. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg. 2002;39(2):110–230.
   PubMed Web of Science ®Google Scholar
• Shteinberg D, Halak M, Shapiro S, et al. Abdominal aortic aneurysm and aortic occlusive disease: a comparison of risk factors and inflammatory response. Eur J Vasc Endovasc Surg. 2000;20(5):462–465.
   PubMed Web of Science ®Google Scholar
• Harrison SC, Smith AJ, Jones GT, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J. 2013;34(48):3707–3716.
   PubMed Web of Science ®Google Scholar
• Tang W, Yao L, Hoogeveen RC, et al. The association of biomarkers of inflammation and extracellular matrix degradation with the risk of abdominal aortic aneurysm: the ARIC study. Angiology. 2019;70(2):130–140.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu G, Wang P. Smoking, hypertension, and GG genotype of the IL-6 rs1800796 polymorphism are independent risk factors for Abdominal Aortic Aneurysm in Han population. Pharmgenomics Pers Med. 2021;14:1115–1121.
   PubMed Web of Science ®Google Scholar
• Kokje VBC, Gäbel G, Koole D, et al. IL-6: a Janus-like factor in abdominal aortic aneurysm disease. Atherosclerosis. 2016;251:139–146.
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86(3):1154–1159.
   PubMed Web of Science ®Google Scholar
• Vázquez-Oliva G, Fernández-Real JM, Zamora A, et al. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J Hum Hypertens. 2005;19(6):457–462.
   PubMed Web of Science ®Google Scholar
• Hirota H, Yoshida K, Kishimoto T. Taga T: continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 1995;92(11):4862–4866.
   PubMed Web of Science ®Google Scholar
• Meléndez GC, McLarty JL, and Levick SP, et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. . 2010;56(2):225–231.
   PubMed Web of Science ®Google Scholar
• Peng C, Stewart AG, Woodman OL, et al. Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments. Front Pharmacol. 2020;11:603926.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Clin Pract Gastroenterol Hepatol. 2018;15(1):11–20.
   Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801.
   PubMed Web of Science ®Google Scholar
• Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2020;110(7):921–937.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2019;16(6):377–386.
   Google Scholar
• Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH. Nat Clin Pract Gastroenterol Hepatol. 2018;15:349–364.
   Google Scholar
• Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103(6):1372–1379.
   PubMed Web of Science ®Google Scholar
• Newsome PN, Buchholtz K, and Cusi K, et al. A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2020;384(12): 1113–1124.
   PubMed Web of Science ®Google Scholar
• Lefere S, Devisscher L, Tacke F. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opin Investig Drugs. 2020;29(2):89–92.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology. 2020;72(3):892–905.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Itoh Y, Yokomizo C, et al. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab Invest. 2010;90(8):1169–1178.
   PubMed Web of Science ®Google Scholar